All In Biotech

Drug Trial Radar · NCT06070857

Study of the Safety, Tolerability, and Pharmacokinetics of LV232 Capsules in Chinese Healthy Volunteers

A Randomized, Double-blind, Placebo-Controlled, Single-Centre,Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of LV232 Capsules in Chinese Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Dec 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

81

Actual

Start

Oct 5, 2023

Primary completion

Nov 17, 2025

Study completion Nov 17, 2025

Sponsor

Lead sponsor
Vigonvita Life SciencesIndustry
Sponsor type
Industry
First posted
Oct 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study consists of 10 dose groups, 8 subjects in each group (male or female), randomly assigned to study drug or placebo group to evaluate the safety, tolerability and pharmacokinetics characteristics.

Conditions

  • Healthy Subjects

Interventions

  • LV232Drug

    Drug: LV232 1mg,2mg,4mg,8mg,15mg,25mg,40mg,60mg,90mg and 120mg

  • PlaceboDrug

    Placebo:1mg,2mg,4mg,8mg,15mg,25mg,40mg,60mg,90mg and 120mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse EventsTime frame: 7 days after treatment
  2. CmaxTime frame: 48 hours after administration
  3. AUC0-tTime frame: 48 hours after administration
  4. AUC0-∞Time frame: 48 hours after administration
  5. AUC0-24hTime frame: 48 hours after administration
  6. TmaxTime frame: 48 hours after administration
  7. t1/2Time frame: 48 hours after administration
  8. CL/FTime frame: 48 hours after administration
  9. Vd/FTime frame: 48 hours after administration
  10. KeTime frame: 48 hours after administration
  11. MRTTime frame: 48 hours after administration
  12. BPTime frame: 48 hours after administration
  13. BRPPTime frame: 48 hours after administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Xuhui Central Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.